Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term neoadjuvant chemotherapy. Found 14 abstracts

Melchior NM, Sachs DB, Gauvin G, Chang C, Wang CE, Sigurdson ER, Daly JM, Aggon AA, Hayes SB, Obeid EI, Bleicher RJ. Treatment times in breast cancer patients receiving neoadjuvant vs adjuvant chemotherapy: Is efficiency a benefit of preoperative chemotherapy?. Cancer medicine. 2020 Feb 25;9(8):2742-51.   PMCID: PMC7163083
Margulis V, Puligandla M, Trabulsi EJ, Plimack ER, Kessler ER, Matin SF, Godoy G, Alva A, Hahn NM, Carducci MA, Hoffman-Censits J. Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial Carcinoma. J Urol. 2019 Nov 08;:101097ju0000000000000644.
Martini A, Jia R, Ferket BS, Waingankar N, Plimack ER, Crabb SJ, Harshman LC, Yu EY, Powles T, Rosenberg JE, Pal SK, Vaishampayan UN, Necchi A, Wiklund NP, Mehrazin R, Mazumdar M, Sfakianos JP, Galsky MD. Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer. Cancer. 2019 May 31;125(18):3155-63.
Masic S, Smaldone MC. Treatment delays for muscle-invasive bladder cancer. Cancer. 2019 Jun 15;125(12):1973-5.   PMCID: Editorial
Del Bene G, Calabro F, Giannarelli D, Plimack ER, Harshman LC, Yu EY, Crabb SJ, Pal SK, Alva AS, Powles T, De Giorgi U, Agarwal N, Bamias A, Ladoire S, Necchi A, Vaishampayan UN, Niegisch G, Bellmunt J, Baniel J, Galsky MD, Sternberg CN, Risc Investigators. Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database. Frontiers in oncology. 2018 Nov;8:463.   PMCID: PMC6252384
Zibelman M, Plimack ER. Systemic therapy for bladder cancer finally comes into a new age. Future Oncol. 2016 Oct;12(19):2227-42.   PMCID: PMC5066115
Bleicher RJ, Sigurdson ER. Inception of Sentinel Lymphadenectomy and Refinement. Curr Probl Cancer. 2012 Sep;36(5):263-91.
Bleicher RJ, Sigurdson ER. Lymphatic Mapping/Sentinel Lymphadenectomy. Current Problems in Cancer. 2012 Sep;36(5):263-91.   PMCID: Not NIH Funded
Chen KT. Axilary Disection. Current Problems in Cancer. 2012 Sep;36(5):245-62.
Shindoh J, Loyer EM, Kopetz S, Boonsirikamchai P, Maru DM, Chun YS, Zimmitti G, Curley SA, Charnsangavej C, Aloia TA, Vauthey JN. Optimal Morphologic Response to Preoperative Chemotherapy: An Alternate Outcome End Point Before Resection of Hepatic Colorectal Metastases. Journal of Clinical Oncology. 2012 Dec;30(36):4566-72.   PMCID: PMC3518730
Dawood S, Cristofanilli M. Inflammatory Breast Cancer: What Progress Have We Made?. Oncology-New York. 2011 Mar;25(3):264-73.   PMCID: not NIH funded
Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, Dirix LY, Levine PH, Lucci A, Krishnamurthy S, Robertson FM, Woodward WA, Yang WT, Ueno NT, Cristofanilli M. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Annals of Oncology. 2011 Mar;22(3):515-23.   PMCID: PMC3105293
Demetri GD, Antonia S, Benjamin RS, Bui MM, Casper ES, Conrad EU, DeLaney TF, Ganjoo KN, Heslin MJ, Hutchinson RJ, Kane JM, Letson GD, McGarry SV, O'Donnell RJ, Paz IB, Pfeifer JD, Pollock RE, Randall RL, Riedel RF, Schupak KD, Schwartz HS, Thornton K, von Mehren M, Wayne J. Soft Tissue Sarcoma. Journal of the National Comprehensive Cancer Network. 2010 Jun;8(6):630-74.   PMCID: not NIH funded
Robertson FM, Bondy M, Yang W, Yamauchi H, Wiggins S, Kamrudin S, Krishnamurthy S, Le-Petross H, Bidaut L, Player AN, Barsky SH, Woodward WA, Buchholz T, Lucci A, Ueno N, Cristofanilli M. Inflammatory Breast Cancer The Disease, the Biology, the Treatment. Ca-a Cancer Journal for Clinicians. 2010 Nov;60(6):351-75.   PMCID: not NIH funded
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term neoadjuvant chemotherapy

neoadjuvant chemotherapy positron-emission-tomography breast-cancer patients therapy internal mammary nodes surgery blue-dye randomized clinical-trial adjuvant breast surgical phase-ii 1992 mascarel i-british journal of cancer-v66-p523 prophylactic mastectomy mammaplasty carcinoma in-situ muscle invasive bladder cancer growth-factor reduction lymph-node biopsy bladder cancer adjuvant chemotherapy pathological response randomized controlled-trial carcinoma-in-situ socioeconomic factors lymph-node dissection Pd-1 inflammatory breast cancer breast cancer body-mass index lymph-node metastases comparing 1991 freitas r-european journal of surgical oncology-v17-p240 soft tissue chemotherapy 1987 war ja-international journal of radiation oncology biology physics-v13-p475 pathologic response guidelines mutations gene-expression long-term survival desmoid tumor Pfizer and Bristol-Myers Squibb and has received institutionally Novartis Combined Modality Therapy Neoplasm Metastasis epithelial-mesenchymal transition induction chemotherapy radical-mastectomy complications of-function manuscript growth-factor receptor methods survival disclosed No writing assistance was utilized in the production of this clinical-trial combination prognostic scoring system urothelial carcinoma The authors have no other relevant affiliations or financial involvement with any Urinary Bladder Neoplasms Neoadjuvant Therapy stage-iii soft tissue extremity sarcoma RISC data base institutionally directed clinical trial support from Horizon Pharma ER Plimack organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those recurrence imatinib mesylate regionalization stem-cell transplantation treatment outcomes delay locally advanced bladder cancer cancer retroperitoneal sarcomas sentinel node immunotherapy bevacizumab carcinoma healthcare policy plus radical cystectomy checkpoint blockade follow-up Eli Lilly has served on advisory boards and as consultant for Genentech human-melanoma cells radical nephroureterectomy upper tract urothelial carcinoma rhoc-gtpase NCCN Guidelines gene-expression signature long-term outcomes 1989 wble b-international journal of radiation oncology biology physics-v17-p703 AstraZeneca and Merck directed clinical trial support from Bristol-Myers Squibb vasculogenic mimicry radiation therapy Immunotherapy NCCN Clinical Practice Guidelines sarcoma gastrointestinal stromal tumors complete axillary dissection cancer management early breast-cancer primary extremity sarcoma liver metastases management rhoc gtpase Ctla-4 radiation-therapy overall survival phase-ii trial pathology trastuzumab mortality european-organization urothelial cancer fine-needle aspiration
Last updated on Wednesday, July 08, 2020